PMID- 24846066
OWN - NLM
STAT- MEDLINE
DCOM- 20150515
LR  - 20220318
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 15
IP  - 5
DP  - 2014
TI  - miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous 
      cell carcinoma.
PG  - 503-8
AB  - MicroRNAs (miRNAs), the endogenous noncoding RNAs, are involved in 
      carcinogenesis. Laryngeal squamous cell carcinoma (LSCC) is the common cancer in 
      head and neck. Whether miRNAs can be used in the diagnosis of LSCC is largely 
      unknown. The purpose of this study was to identify whether miRNAs could be use as 
      potential biomarkers for LSCC diagnosis. The expression levels of miR-21, 
      miR-106b and miR-375, in LSCC tissues and paired nontumor tissues were first 
      quantitatively analyzed by reverse transcription-polymerase chain reaction. Then, 
      the relationships between their expression levels and clinicopathological 
      parameters of patients with LSCC were further determined. We found that these 
      miRNAs' expression levels were significantly different between LSCC tissues and 
      adjacent normal tissues. Two miRNAs, miR-21 and miR-106b were found up-regulated 
      in cancer tissues (P=0.0012 and P<0.001, respectively), while miR-375 
      down-regulated (P<0.001). Moreover, miR-21 and miR-106b levels were found 
      significantly increased in poorly (G3)/moderately differentiated (G2) cancer 
      tissues comparing with well differentiated (G1) and dysplasia (D) tissues 
      (P<0.001, respectively). Their levels were also positively associated with lymph 
      node metastasis (P<0.05) and TNM stages (P<0.01). However, miR-375 expression 
      level was only found negatively associated with TNM stages. Our preliminary data 
      suggest that three miRNAs, miR-21, miR-106b and miR- 375 might become novel tumor 
      markers for LSCC diagnosis.
FAU - Yu, Xing
AU  - Yu X
FAU - Wu, Yibo
AU  - Wu Y
FAU - Liu, Yang
AU  - Liu Y
FAU - Deng, Hongxia
AU  - Deng H
FAU - Shen, Zhisen
AU  - Shen Z
FAU - Xiao, Bingxiu
AU  - Xiao B
FAU - Guo, Junming
AU  - Guo J
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Biochemistry 
      and Molecular Biology, Ningbo University School of Medicine, 315211 Ningbo, 
      China. junmingguo@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN106 microRNA, human)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MIRN375 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoma, Squamous Cell/*blood/*diagnosis/pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*blood/*diagnosis/pathology
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - MicroRNAs/*blood
MH  - Middle Aged
EDAT- 2014/05/23 06:00
MHDA- 2015/05/16 06:00
CRDT- 2014/05/22 06:00
PHST- 2013/03/11 00:00 [received]
PHST- 2013/11/11 00:00 [revised]
PHST- 2014/05/22 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2015/05/16 06:00 [medline]
AID - CPB-EPUB-60563 [pii]
AID - 10.2174/1389201015666140519110616 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2014;15(5):503-8. doi: 10.2174/1389201015666140519110616.